Last updated: July 31, 2026
XOPENEX (levalbuterol) is a mature short-acting beta2-adrenergic agonist with limited remaining investment value as a standalone pharmaceutical asset. The product has FDA-approved nebulized and metered-dose inhaler formulations, but its core composition and formulation protections expired or became commercially ineffective years ago. Generic levalbuterol products compete directly with the brand, while albuterol remains the primary lower-cost alternative. XOPENEX can generate residual cash flow through brand loyalty, payer coverage, and pediatric or nebulizer use, but it does not have a meaningful exclusivity-driven growth profile.
What is XOPENEX and how does levalbuterol work?
XOPENEX is the brand name for levalbuterol, the R-enantiomer of racemic albuterol. It activates beta2-adrenergic receptors in bronchial smooth muscle and produces rapid bronchodilation.
The product is used for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease-related bronchospasm. XOPENEX is available in:
| Product |
Dosage form |
Primary use |
Original commercial sponsor |
| XOPENEX Inhalation Solution |
Nebulized solution |
Acute bronchospasm |
Sepracor |
| XOPENEX Concentrate |
Concentrated nebulizer solution |
Acute bronchospasm after dilution |
Sepracor |
| XOPENEX HFA |
Metered-dose inhaler |
Acute bronchospasm |
Sepracor |
Sepracor developed and commercialized XOPENEX before being acquired by Dainippon Sumitomo Pharma in 2009. Dainippon Sumitomo later changed its corporate name to Sumitomo Pharma. The product sits within a broader portfolio rather than operating as a separately reported public-company asset.
What is the FDA regulatory status of XOPENEX?
The FDA approved XOPENEX Inhalation Solution in 1999, XOPENEX Concentrate in 2002, and XOPENEX HFA in 2005. The product is approved as an inhaled short-acting bronchodilator.
FDA approval and labeling timeline
| Milestone |
Product |
Approximate date |
| Original FDA approval |
XOPENEX Inhalation Solution |
1999 |
| Approval of concentrated nebulizer formulation |
XOPENEX Concentrate |
2002 |
| Approval of HFA metered-dose inhaler |
XOPENEX HFA |
2005 |
| Generic levalbuterol nebulizer competition |
Inhalation solution |
2010s |
| Generic levalbuterol HFA competition |
Metered-dose inhaler |
2010s |
XOPENEX is not a biologic, so biosimilar regulation does not apply. Competition proceeds through abbreviated new drug applications, or ANDAs, rather than the 351(k) biosimilar pathway.
The principal FDA commercial issue is substitution. Generic levalbuterol inhalation solutions can generally compete through pharmacy and hospital channels, while device-specific inhaler approvals may create more practical switching friction than the underlying active ingredient would suggest.
When did XOPENEX lose exclusivity?
XOPENEX lost meaningful market exclusivity years ago. The core active ingredient, levalbuterol, is no longer protected by a commercially significant composition-of-matter patent.
The original patent strategy focused on the R-enantiomer of albuterol, pharmaceutical compositions, inhalation formulations, and methods of treating bronchospasm. Those rights were filed and prosecuted in the 1990s and early 2000s. Standard patent terms for those families generally expired during the 2010s, subject to individual patent-term-adjustment and patent-term-extension calculations.
XOPENEX therefore has no realistic small-molecule exclusivity event that would restore pricing power. Any remaining rights would be narrow, product-specific, or commercially difficult to enforce.
XOPENEX exclusivity profile
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Core composition patents |
Expired or commercially exhausted |
| Nebulized formulation patents |
Expired or no longer material to market access |
| HFA formulation protection |
Expired or subject to generic competition |
| Pediatric exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Biologic exclusivity |
Not applicable |
| Current Orange Book moat |
Limited to none |
XOPENEX does not have the type of remaining exclusivity associated with a protected specialty drug, a recently approved inhaled product, or a biologic.
What patents protect XOPENEX?
The historical patent estate covered levalbuterol and inhaled delivery. The economically relevant patent categories were:
- Patents covering the R-isomer of albuterol.
- Pharmaceutical compositions containing levalbuterol.
- Nebulized aqueous solutions.
- Metered-dose inhaler formulations.
- Methods for treating bronchospasm while reducing exposure to the S-isomer contained in racemic albuterol.
The commercial value of these categories has declined because patent terms have run out and generic manufacturers have entered the market.
Does XOPENEX have active Orange Book patents?
XOPENEX does not appear to have an active Orange Book patent position capable of materially delaying ordinary generic entry. Historical Orange Book listings may remain relevant to litigation records and abbreviated-approval history, but they do not establish a current commercial barrier by themselves.
The precise Orange Book position can vary by product presentation, marketing status, and FDA listing updates. The investment conclusion is unchanged: XOPENEX is an off-patent inhaled prescription drug with generic competition.
Which companies are challenging XOPENEX?
Generic competition has come from manufacturers of levalbuterol inhalation products, including companies such as Teva Pharmaceuticals and other ANDA sponsors. The competitive set can change by dosage form and presentation.
Relevant competitors include:
| Competitor |
Active ingredient |
Delivery form |
Competitive impact |
| Generic levalbuterol |
Levalbuterol |
Nebulized solution |
Direct substitution |
| Generic levalbuterol HFA |
Levalbuterol |
Metered-dose inhaler |
Direct product competition |
| ProAir and generic albuterol |
Albuterol |
HFA inhaler |
Lower-cost therapeutic alternative |
| Ventolin and generic albuterol |
Albuterol |
HFA inhaler |
Broad formulary presence |
| Albuterol nebulizer solutions |
Albuterol |
Nebulized solution |
High-volume alternative |
The most important threat is not a single patent challenger. It is the combined effect of generic levalbuterol and lower-priced racemic albuterol products.
How does XOPENEX compare with albuterol?
Levalbuterol is the R-enantiomer of albuterol, while conventional albuterol contains both R- and S-enantiomers. The original commercial thesis was that isolating the active R-enantiomer could preserve bronchodilation while reducing adverse effects associated with the S-isomer.
Clinical and economic differentiation has been limited. Some patients and clinicians prefer levalbuterol because of perceived tolerability or individual response, but broad evidence has not established a consistent advantage sufficient to support a durable premium across the market.
| Factor |
XOPENEX / levalbuterol |
Albuterol |
| Pharmacology |
R-enantiomer |
Racemic mixture |
| Onset |
Rapid |
Rapid |
| Use |
Rescue bronchodilation |
Rescue bronchodilation |
| Generic availability |
Yes |
Extensive |
| Typical price position |
Higher historically |
Lower |
| Payer preference |
Variable |
Usually stronger |
| Differentiation |
Tolerability and patient-specific response |
Cost, availability, familiarity |
| Patent status |
Mature and largely unprotected |
Mature and largely unprotected |
Albuterol has the larger installed base, broader formulary coverage, and deeper generic supply. XOPENEX’s commercial defense depends on patient-level prescribing preferences rather than patent exclusivity.
What generic entry risks exist for XOPENEX?
Generic entry risk is already realized rather than prospective. The principal risks are:
- Continued erosion of brand prescription volume.
- Pharmacy substitution toward generic levalbuterol.
- Hospital and Medicaid preference for generic nebulizer products.
- Formulary exclusion or higher patient cost sharing for brand XOPENEX.
- Price compression in contracts with wholesalers and institutional buyers.
- Therapeutic substitution to generic albuterol.
The HFA inhaler may retain modest brand protection through device familiarity, physician prescribing habits, and patient training requirements. That protection is commercial rather than legal. It can delay switching but does not prevent it.
What is the litigation status of XOPENEX?
The major XOPENEX patent disputes occurred during the period when generic levalbuterol manufacturers sought FDA approval. Those disputes were associated with ANDA filings, patent certifications, and claims involving levalbuterol formulations and methods of use.
No current, high-value patent litigation appears to create a credible new exclusivity period for XOPENEX. Any historical Hatch-Waxman litigation is more relevant to understanding generic launch timing than to assessing present-day investment value.
Paragraph IV challenge exposure
Generic levalbuterol ANDA filings could have included Paragraph IV certifications against listed patents. Such certifications trigger potential patent litigation under the Hatch-Waxman Act but do not permanently protect the brand. Once the relevant patents expire or are invalidated, the generic approval pathway remains available.
For investors, the material point is that Paragraph IV risk is no longer an emerging catalyst. The market has moved from litigation risk to mature generic erosion.
What formulations are protected by XOPENEX patents?
Historically, the most commercially important formulation distinctions were:
Nebulized inhalation solution
The nebulized product is used widely in pediatric, emergency, outpatient, and home-care settings. Generic aqueous levalbuterol solutions have materially reduced the value of formulation patents.
Concentrated nebulizer solution
The concentrate requires dilution before administration. Its narrower use and older product profile provide limited strategic value. It is more exposed to generic substitution and institutional procurement pressure.
XOPENEX HFA inhaler
The HFA product replaced older chlorofluorocarbon-based inhaler technology. Device and formulation patents were relevant during the transition to HFA delivery, but those protections no longer provide a meaningful barrier to generic competition.
Device complexity can still affect launch timing because generic inhalers must satisfy FDA requirements for dose uniformity, actuator performance, container-closure systems, and human-factor considerations. These requirements create development costs but do not establish durable exclusivity after approval.
How strong is the XOPENEX patent estate?
The patent estate is weak from an investment perspective.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Remaining term |
No material term expected |
| Formulation protection |
Narrow and largely expired |
| Device protection |
Limited practical value |
| Method-of-use protection |
Not a meaningful commercial barrier |
| Generic substitution risk |
High |
| Ability to raise price |
Low |
| Litigation leverage |
Low |
| Manufacturing complexity |
Moderate for HFA, low for solution |
| Overall moat |
Weak |
The drug’s molecular simplicity and long commercial history favor generic manufacturing. Nebulized solutions are particularly vulnerable because they do not require highly complex delivery technology. HFA inhalers require more technical development, but multiple suppliers and established inhaler manufacturing capabilities reduce the barrier.
What is the commercial outlook and revenue exposure?
Sumitomo Pharma does not generally report XOPENEX as a separately disclosed major revenue segment. That limits the ability to calculate product-level revenue growth, margins, or concentration directly from public company filings.
XOPENEX is best analyzed as a mature tail product. Its remaining revenue is likely supported by:
- Brand-prescribing physicians.
- Patients stable on the product.
- Institutional or pediatric use.
- Partial reimbursement in selected plans.
- Limited switching in patients who report better tolerability than with albuterol.
- Channel-specific demand for branded inhalers.
Revenue pressure comes from generic pricing, formulary controls, and the low cost of albuterol. The product is unlikely to become a material growth driver for Sumitomo Pharma absent a new formulation, licensing transaction, or lifecycle-management strategy.
Investment scenario analysis
| Scenario |
Commercial outcome |
Investment implication |
| Base case |
Gradual brand decline with residual demand |
Low-growth cash-flow tail |
| Downside |
Faster formulary exclusion and generic substitution |
Accelerated revenue erosion |
| Upside |
Stable niche use and limited brand switching |
Modest cash-flow preservation |
| Strategic case |
New delivery technology or licensing |
Value depends on new asset, not legacy XOPENEX |
The downside is more likely to affect the pace of decline than the existence of the decline. There is no clear patent-based upside case.
Are there licensing deals involving XOPENEX?
Sepracor was the original developer and commercial sponsor. The acquisition of Sepracor by Dainippon Sumitomo Pharma transferred control of XOPENEX into the Japanese company’s portfolio.
No current licensing transaction is central to the XOPENEX investment thesis. Historical development and commercialization arrangements may have affected regional rights, but they do not alter the drug’s mature exclusivity status.
What geographic coverage does XOPENEX have?
XOPENEX has had commercial relevance primarily in the United States, where levalbuterol was positioned as a branded alternative to albuterol. Geographic value outside the United States is more limited because:
- Albuterol is widely available globally.
- The clinical differentiation of levalbuterol is modest.
- Generic substitution is common.
- Regulatory and reimbursement systems may not support a premium for the single-enantiomer product.
The United States remains the principal market for assessing the product’s brand value, Orange Book history, and generic competition.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers differ by dosage form.
Nebulized solutions are relatively accessible to established sterile-liquid manufacturers. Key requirements include sterile production, container-closure integrity, assay control, preservative management where applicable, and reliable unit-dose packaging.
HFA inhalers require greater technical capability. Manufacturers must control aerosol particle size, emitted dose, valve performance, actuator geometry, canister compatibility, and device consistency. These requirements can limit the number of immediate competitors, but they do not create a lasting patent moat once generic products are approved.
The main remaining barrier is execution, not intellectual property.
Is XOPENEX an attractive pharmaceutical investment?
XOPENEX is unattractive as a standalone growth investment. It may retain value as a mature branded cash-flow product, but its fundamentals are constrained by:
- Expired exclusivity.
- Generic levalbuterol competition.
- Strong albuterol substitution.
- Limited clinical differentiation.
- Lack of separately reported product economics.
- No visible patent catalyst.
- Low probability of a new premium pricing cycle.
A buyer evaluating the asset would focus on cash-flow durability, manufacturing cost, net pricing, channel concentration, inventory obligations, and the remaining life of brand demand. Strategic value could exist if XOPENEX were bundled with a respiratory portfolio, but the legacy product alone would not justify a significant acquisition premium.
Key Takeaways
- XOPENEX is levalbuterol, the R-enantiomer of albuterol.
- FDA approvals cover nebulized solution, concentrate, and HFA inhaler formulations.
- Core patent and regulatory exclusivity has expired.
- Generic levalbuterol and generic albuterol are the principal competitive threats.
- Biosimilar risk does not apply because XOPENEX is a small-molecule drug.
- Historical Paragraph IV litigation is no longer a current exclusivity catalyst.
- The Orange Book does not provide a meaningful active patent moat.
- HFA inhaler manufacturing is more complex than nebulized-solution production, but the barrier is technical rather than durable.
- Sumitomo Pharma does not disclose XOPENEX as a major standalone revenue driver.
- The product is best valued as a declining or stable niche cash-flow asset, not as a growth franchise.
FAQs
Does XOPENEX still have market exclusivity?
No meaningful market exclusivity remains. The product competes with generic levalbuterol and albuterol.
Is levalbuterol more effective than albuterol?
Levalbuterol can provide effective bronchodilation, but broad clinical evidence has not established a consistent advantage that supports a universal premium over albuterol.
Can generic manufacturers substitute levalbuterol for XOPENEX?
Generic substitution depends on the dosage form, state law, pharmacy rules, payer policy, and prescription instructions. Generic levalbuterol directly competes with XOPENEX.
Does XOPENEX have biosimilar competition?
No. XOPENEX is a small-molecule drug and is subject to generic, not biosimilar, competition.
What would increase the value of the XOPENEX franchise?
A new proprietary inhaler, pediatric delivery system, combination product, licensing arrangement, or manufacturing-cost improvement could increase value. The legacy XOPENEX products do not have a clear patent-based growth catalyst.
References
- U.S. Food and Drug Administration. (1999). XOPENEX (levalbuterol hydrochloride) inhalation solution: Approved product labeling.
- U.S. Food and Drug Administration. (2002). XOPENEX Concentrate (levalbuterol hydrochloride) inhalation solution: Approved product labeling.
- U.S. Food and Drug Administration. (2005). XOPENEX HFA (levalbuterol tartrate) inhalation aerosol: Approved product labeling.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- Sumitomo Pharma Co., Ltd. (2024). Annual securities report and corporate disclosures.
- U.S. Patent and Trademark Office. (2024). Patent term and patent-term-adjustment guidance.
